Tanning & pigmentation
Melanotan II produced measurable darkening in an early phase-I pilot.
Explore the research →MELANOCORTIN & PIGMENTATION RESEARCH
Melanotan II
An experimental peptide best known for tanning and pigmentation, with additional interest around sexual response. It is not an approved medicine.
Skin pigmentationMC1R signallingSexual response
A real early human signal with a large safety and approval gapSmall 1990s studies showed pigmentation and erectile responses after subcutaneous exposure. They did not establish a licensed tanning product, a safe consumer schedule or long-term skin outcomes.
FOLLOW THE FULL PICTUREFrom interest to evidence, quality and the numbers.
Why are people interested in Melanotan II?
Melanotan II first attracted attention because early human studies produced visible skin darkening. Researchers also noticed effects on sexual response, creating a second reason for interest. Those two effects — pigmentation and libido — still drive most of the conversation around it today.
Libido & sexual response
Erections and increased desire were observed in small placebo-controlled crossover studies.
Explore the research →Appetite
Reduced appetite is frequently discussed because nausea and decreased appetite appeared during early exposure.
Explore the research →Tanning with less UV exposure
People hope that a pharmacological tan may reduce the need for sun or sunbeds.
Explore the research →THE SCIENCE BIT
More than one melanocortin signal.
Melanotan II is a cyclic alpha-MSH analogue that acts at several melanocortin receptors. MC1R links it with skin pigmentation, while central melanocortin pathways help explain appetite and sexual-response research.
These different targets are why it cannot be described as a skin-only peptide. Early human findings do not establish the safety of unregulated cosmetic use.
See the studies & trials →- MC1R
- Skin-pigment signalling
- Central receptors
- Appetite and sexual-response research
- Multiple targets
- Effects extend beyond skin
How this connects to the research
Early human research with an unapproved-product context.
FROM MOLECULE TO TISSUE
Where Melanotan II connects with the body
These are the tissues and biological systems behind the interest in Melanotan II.
- Skin
- Melanocyte and pigmentation responses.
- Brain
- Central melanocortin pathways.
- Whole-body context
- Multiple receptor effects.
The research behind the interest
Tanning & pigmentation
Tanning is by far the main reason Melanotan II became well known, with early human experiments showing that it can visibly darken skin pigmentation.
Only three men entered the 1996 pilot. Pigmentation appeared after five active doses, so the signal is human but the dataset is extremely small.
Early human signalExplore the studies →Libido & sexual response
An unexpected part of the early research was its effect on sexual desire and erections, which created a second major area of interest around the compound.
The programmes involved ten men each and also reported nausea, yawning and stretching. They did not create an approved Melanotan II treatment.
Small controlled human studiesExplore the studies →Appetite
Reduced appetite is sometimes discussed as another effect, although it appeared alongside side effects in small early studies rather than as a proven weight-management treatment.
Those were adverse-effect signals in tiny erectile-dysfunction studies, not evidence of safe or durable weight management.
Human observation; efficacy unprovenExplore the studies →Tanning with less UV exposure
Some people are interested in achieving darker pigmentation with less time in the sun or on sunbeds, although a tan produced this way should not be mistaken for reliable UV protection.
Pigmentation is not clinically adequate UV protection. Melanotan II has not been shown to prevent sunburn, photoageing or skin cancer.
Claim not establishedExplore the studies →Studies & trials
Studies & trials
Original publication · PubMed · trial registry where availablePilot phase-I pigmentation study ↗
Three healthy male volunteers
SubcutaneousAlternating active and saline days; five active dosesTwo weeks
Two participants developed measurable facial and body pigmentation.
Mild nausea occurred at most dose levels; somnolence and fatigue appeared at the highest exposure in one participant.
Psychogenic erectile-dysfunction crossover study ↗
Ten men with psychogenic erectile dysfunction
SubcutaneousSingle 0.025 mg/kg research exposureSix-hour monitored session
Clinically apparent erections developed in eight of ten men.
Nausea, yawning, stretching and reduced appetite were more frequent than with placebo.
Organic-risk erectile-dysfunction crossover study ↗
Ten men with erectile dysfunction and organic risk factors
Subcutaneous0.025 mg/kg on two monitored occasionsSix-hour sessions
Rigidity and reported desire increased versus placebo.
Four of 19 active injections were associated with severe nausea.
Evidence snapshot
Evidence snapshot
Separate dimensions, not one overall score◎
Human evidenceDeveloping
3/5 evidence depth
Tiny controlled human studies measured pigmentation, erections and acute adverse effects.
✓
Clinical efficacyLimited
2/5 evidence depth
No approved indication or modern confirmatory efficacy programme exists.
◇
Safety evidenceLimited
2/5 evidence depth
Nausea, fatigue, yawning and erections were reported; case reports describe serious events, while long-term risk remains unresolved.
⌁
Preclinical evidenceDeveloping
3/5 evidence depth
Melanocortin-receptor and animal research support several mechanisms.
HOW TO READ THESE SCORESDeveloping preclinical evidence · developing human evidence
These are editorial evidence-depth ratings on a 1–5 scale, not a statistical result or a single scientific formula. They summarise how much relevant evidence is present in each separate category and how mature that evidence is.
Human evidenceHow much direct research in people is available and how developed it is.
Clinical efficacyWhether human studies demonstrate meaningful outcomes for the claims being discussed.
Safety evidenceHow much human safety, tolerability and longer-term follow-up information is available.
Preclinical evidenceThe depth of laboratory and animal research supporting biological plausibility.
EVIDENCE LANDSCAPEMelanotan IIBiology → route → human outcome
Pigmentation and erectile responses in tiny studies
No approved tanning, sexual-health or weight indication
Pigment lesions, product quality and cumulative exposure
Keep each claim attached to its route and outcome
An active biological pathway can justify a trial. It cannot make an untested formulation, indication or long-term schedule evidence-based.
From promising signals to human evidencePreclinical research can reveal promising biological signals. Human studies show how far those signals have translated into real-world outcomes.
What people are exploring
COMMUNITY · USE CASES & EXPERIENCE
What people want to change with Melanotan II
People mainly explore Melanotan II for a faster tan, less time in the sun, libido effects and appetite reduction. Early human work confirms biological activity but does not provide modern product-quality or long-term safety evidence.
Explore the everyday goalsConceptual scientific illustration
THE PRACTICAL ATTRACTION
The goals behind the interest
What the desired change means in daily life, and what makes an experience useful to understand.
A darker tan or easier pigmentation
Cosmetic interest centres on skin colour and the perception of tanning more readily. Appearance changes attract attention, but the desired tan is not evidence that sun exposure has become safe.
- What makes a report informative
- Comparable skin photographs and any changing pigmented lesions.
- What can muddy the picture
- UV exposure and baseline skin type strongly affect the appearance.
Libido and sexual-response effects
Some interest concerns increased desire or erections, reflecting activity beyond skin pigmentation. An unwanted prolonged erection is an adverse event, not a sign of superior sexual performance.
- What makes a report informative
- Sexual wellbeing separated from unwanted or prolonged effects.
- What can muddy the picture
- Melanocortin effects can be variable; arousal does not establish a reliable treatment benefit.
Appetite changes alongside tanning
Reduced appetite is sometimes discussed as an additional effect. This needs to be separated from nausea or feeling unwell rather than being treated as a desirable weight-loss outcome.
- What makes a report informative
- Hunger, food enjoyment and gastrointestinal symptoms separately.
- What can muddy the picture
- Nausea-related food avoidance can be mistaken for beneficial appetite control.
PUT THE EXPERIENCE IN CONTEXT
How the goals compare with the research
Open an area to distinguish human findings from laboratory explanations.
Faster tanning
Visible change and darker freckles or moles are commonly described.
Human findings & limits
A three-person pilot documented pigmentation after five active doses.
Laboratory & animal context
MC1R-driven eumelanin biology explains the signal.
What this means: A genuine effect supported by an exceptionally small dataset.
Less sun exposure
The goal is often colour with shorter UV sessions.
Human findings & limits
No trial established sunscreen-equivalent protection or reduced UV harm.
Laboratory & animal context
Pigment change is not the same as adequate photoprotection.
What this means: Do not translate colour into protection from sunburn or cancer.
Libido and erections
Spontaneous erections and increased desire are sometimes sought deliberately.
Human findings & limits
Two ten-person studies found responses alongside frequent nausea and yawning.
Laboratory & animal context
Central melanocortin pathways support the mechanism.
What this means: An early signal, not an approved treatment.
Appetite reduction
Reduced hunger is sometimes treated as a secondary benefit.
Human findings & limits
Decreased appetite appeared as an adverse effect; weight loss was not tested.
Laboratory & animal context
Melanocortin signalling participates in energy balance.
What this means: A mechanistic extension, not weight-management efficacy.
Dose & duration
DOSE & DURATION
Research protocols · community patterns · calculator toolsSee the numbers in their proper context
See the amount, how often it was used and how long each study ran. Published human research and community descriptions each carry their own source label, so you can see where the numbers came from.
Source matters. The figures below show authorised, human-research or community-described protocols in their original context — not a personalised recommendation.
There is no authorised Melanotan II dose or evidence-based consumer loading and maintenance schedule.
No structured human dosing protocol has been added for this compound. That should not be interpreted as evidence for a community dosing schedule.
COMMUNITY DISCUSSION
Anecdotal community pattern · unapproved productWhat people commonly discuss
STARTING APPROACHES
Online schedules often describe 0.25 mg or less to gauge acute effects; this is anecdotal, not a validated safe starting dose.
DURATION / CYCLES
Short daily or alternate-day ‘loading’ periods recur, but no controlled study validates them.
MAINTENANCE DISCUSSION
Intermittent 0.25–0.5 mg patterns are discussed; no safe maintenance interval or lifetime exposure limit exists.
Community patterns are anecdotal and unvalidated unless a linked human study independently supports the same approach.
COMMUNITY-REPORTED PRACTICEInjection patterns people commonly discussPopular uses · route · site discussion · timing · durationCommon anecdotal consensus
TanningReduced UV exposureLibidoAppetite reduction
ROUTE PEOPLE DISCUSS
Subcutaneous injection and nasal products are discussed; neither is an approved consumer route.
INJECTION-SITE DISCUSSION
No site has been shown to improve pigmentation or reduce systemic effects.
TIMING PEOPLE DISCUSS
Evening use is sometimes described because nausea and flushing can occur, but timing has not been compared clinically.
DURATION / CYCLE DISCUSSION
Community descriptions separate loading from maintenance; neither phase is validated.
What the evidence supports
The tiny phase-I programme cannot calibrate retail vials, nasal sprays, maintenance or long-term skin safety.
Community reports describe what people say they do; they are not instructions, validated protocols, or evidence that a particular injection site or timing improves outcomes.CALCULATOR TOOLS
Work with the numbers
Convert amounts, concentration, liquid volume and vial requirements. These tools do the arithmetic; they do not select a dose.
NEED HELP READING THE NUMBERS?Source labels, routes and dose termsOpen guide +
HOW WE LABEL NUMBERSKnow where a dose came from before you compare it.
Authorised labelHuman trialCommunity-describedBEFORE THE NUMBERS: CHECK THE PRODUCT
Understand peptide testing →A dose only means something if the vial contains what the label says.
Purity, identity, quantity, sterility and endotoxin testing answer different questions. Learn how to read a COA and why a high purity percentage is not the same as confirming the amount in the vial.
READ THIS PAGE IN THREE STEPS
Understand the study before the number
A dose only makes sense alongside the population, route, frequency and duration. Start with where the number came from, then look at how it was delivered and how long the study actually ran.
1Source
Was it an authorised label, a human trial or a community-described pattern?
2Route & frequency
How was it given, and how often? The same number by a different route may not mean the same exposure.
3Duration
Was this one dose, a short trial or long-term treatment? A study window is not automatically a recommended cycle.
ROUTES EXPLAINED
Plain-English guideWhat do the injection types mean?
Route means how a compound was delivered. It affects absorption and can completely change how a study should be interpreted.
SubQ / SCSubcutaneous
An injection into the fatty layer just under the skin.
Common in peptide and metabolic-drug studies. It usually aims for systemic absorption rather than treating only the spot injected.IMIntramuscular
An injection into muscle tissue.
Muscle can absorb a medicine differently from fat. An IM amount should not be assumed to be equivalent to a SubQ amount.IVIntravenous
Delivered directly into a vein.
This gives immediate bloodstream exposure and is commonly used in supervised research or clinical settings. It is not interchangeable with a home injection route.INIntranasal
Delivered through the nose rather than by injection.
The amount delivered depends on formulation and device. A spray count alone does not tell you the dose unless concentration and spray volume are known.Other routes you may see:Oral = swallowed.Topical = applied to skin or another surface.Implant = a formulation placed under the skin by a trained professional.
CALENDAR SETUP
Exposure and risk context
Unapproved product · no established safe tanning scheduleEarly human experiments and online loading descriptions do not establish safe amounts, maintenance intervals or lifetime exposure. Reported serious harms make a routine tanning preset inappropriate. You can retain an existing record without a suggested loading sequence.
Form and route: Research exposures do not establish a routine tanning regimen
The planner keeps amounts and repeat patterns blank for this compound. Use its formulation guide to record an independently specified schedule.
PLAIN-ENGLISH GLOSSARYWhat do the dose terms mean?Open glossary +
mgmilligram
One thousand micrograms (mcg).
mcg / μgmicrogram
One thousandth of a milligram.
mcg/kgweight-based dose
The amount is calculated for each kilogram of body weight.
IUinternational unit
A measure of biological activity used for some medicines; it cannot be converted to mg without compound-specific information.
Routehow it was given
For example SubQ, IM, IV, intranasal, oral or topical.
Frequencyhow often
For example once daily, twice weekly or every seven days.
Titrationplanned step-up or step-down
A protocol changes the amount over time rather than using one fixed amount throughout.
Half-lifehow quickly levels fall
The time taken for the amount of a compound in the body to reduce by roughly half. It can influence study timing but does not by itself define a schedule.
Cyclea defined period of use
Usually means an on-period followed by a stop or review. Many community 'cycles' have not been clinically validated.
Maintenancea continuing phase
A longer-term amount or interval used after an initial phase when a study or authorised treatment actually defines one.
Reconstitutionturning powder into solution
Adding a specified liquid to a freeze-dried vial so a concentration can be calculated.
U-100 unitssyringe volume markings
100 units equals 1 mL on a U-100 insulin syringe. The markings show volume, not peptide mass.
Often combined with
OFTEN COMBINED WITH
Community rationale · component roles · evidence boundaryWhy people explore pairings with Melanotan II
See the thinking behind community-named stacks, the different role each component is proposed to play, and how much of that idea has actually been tested as a combination.
Potential first, evidence in context. Pairings are usually explored because their research stories appear complementary. That makes them interesting to study, but does not yet prove extra benefit or safety.
CURRENT COMPOUNDMelanotan II
→
OFTEN EXPLORED WITHMelanotan II + UV exposure
Melanotan II + Sun or sunbed exposure
→
OFTEN EXPLORED WITHMelanotan II + PDE5 inhibitor
Melanotan II + Tadalafil or sildenafil
→
OFTEN EXPLORED WITHMelanotan II + skin surveillance
Melanotan II + Baseline and follow-up skin checks
Combination-specific human research is the strongest evidence for what a pairing adds. Evidence for either ingredient alone should not be silently transferred to the combination.
＋
OFTEN EXPLORED WITH
Explore →＋Melanotan II + UV exposure
Melanotan II + Sun or sunbed exposureWHY IT IS EXPLOREDUV is often added to deepen visible pigmentation.
Melanotan II does not make UV exposure safe; established skin-cancer and photoageing risks remain.OFTEN EXPLORED WITH
Explore →＋Melanotan II + PDE5 inhibitor
Melanotan II + Tadalafil or sildenafilWHY IT IS EXPLOREDDiscussed around erectile response.
Combination efficacy and priapism risk are unestablished; a prolonged or painful erection is an emergency.OFTEN EXPLORED WITH
Explore →Melanotan II + skin surveillance
Melanotan II + Baseline and follow-up skin checksWHY IT IS EXPLOREDPigment darkening can make mole change harder to interpret.
Surveillance may identify change but cannot make an unapproved product safe.Safety context
SAFETY & UNCERTAINTY
Pigment change, systemic effects and an unregulated supply chain
What the current evidence saysKnown short-term effects include nausea, flushing, yawning, fatigue and spontaneous erections. Changing moles, priapism and other serious events appear in case reports; long-term melanoma risk is unresolved rather than proven or excluded.
01 · OBSERVEDPublished safety findings
The summary above reflects the human or preclinical evidence currently represented on this profile.
02 · UNCERTAINGaps still matter
Limited follow-up, small studies or absent controlled trials can leave uncommon and longer-term risks unresolved.
03 · CONTEXTProduct and regulatory status
Route, product identity, quality and regulatory status can materially change the safety context; see the linked status sources below.
Why this matters
A new or changing pigmented lesion needs prompt assessment. A painful erection or one lasting four hours is an emergency.
Sources & current status
READ FURTHER
Sources & current status
Follow the professional sources used across this profile, then see how the compound is currently described in regulatory and research terms.
KEY RESEARCH RECORD
7 sourcesSources used on this profile
Bibliographic recordPilot phase-I pigmentation studyPubMed ↗Bibliographic recordPsychogenic erectile-dysfunction crossover studyPubMed ↗Original publicationOrganic-risk erectile-dysfunction crossover studyJournal / DOI ↗Bibliographic recordOrganic-risk erectile-dysfunction crossover studyPubMed ↗Case reportSafety and uncertaintyMelanoma-associated case report ↗Professional sourceUnited KingdomMHRA products database ↗Professional sourceUnited StatesDrugs@FDA ↗
CURRENT STATUS
How to interpret its position today
No UK-authorised medicine identified
Melanotan II is presented as an experimental compound. Product identity, quality and supply sit outside an approved prescribing pathway.
MHRA products database ↗No FDA-approved therapeutic product identified
A published experiment is not approval for safety and efficacy.
Drugs@FDA ↗Profile reviewed against its linked source record on 20 September 2026. See how evidence is assessed.